Jefferies Financial Group Inc. purchased a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,400,048 shares of the company's stock, valued at approximately $26,755,000. Jefferies Financial Group Inc. owned about 0.07% of Kenvue as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of KVUE. Elyxium Wealth LLC acquired a new stake in shares of Kenvue during the 4th quarter worth about $26,000. Johnson Financial Group Inc. acquired a new position in Kenvue in the second quarter valued at about $26,000. MV Capital Management Inc. acquired a new position in Kenvue in the fourth quarter valued at about $28,000. CoreCap Advisors LLC boosted its stake in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after buying an additional 591 shares during the period. Finally, Reflection Asset Management purchased a new position in Kenvue during the fourth quarter worth about $32,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Trading Down 0.1%
KVUE opened at $19.20 on Friday. The business has a fifty day moving average price of $19.14 and a 200 day moving average price of $18.24. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $20.82. The stock has a market capitalization of $36.87 billion, a price-to-earnings ratio of 22.06, a PEG ratio of 1.38 and a beta of 0.47.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. Kenvue's revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were paid a dividend of $0.21 per share. The ex-dividend date was Wednesday, August 12th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue's payout ratio is currently 96.55%.
Analysts Set New Price Targets
Several research firms recently weighed in on KVUE. Barclays lifted their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a report on Tuesday, July 21st. UBS Group lowered their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Zacks Research downgraded Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Finally, Weiss Ratings raised Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $19.27.
Get Our Latest Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
See Also
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
